

Elizabeth P Henske

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1426859/publications.pdf>

Version: 2024-02-01

61
papers

12,671
citations

201674
27
h-index

128289
60
g-index

66
all docs

66
docs citations

66
times ranked

27046
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
3	The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma. Cancer Cell, 2014, 26, 319-330.	16.8	665
4	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports, 2018, 23, 313-326.e5.	6.4	523
5	Unjamming and cell shape in the asthmatic airway epithelium. Nature Materials, 2015, 14, 1040-1048.	27.5	484
6	Tuberous sclerosis complex. Nature Reviews Disease Primers, 2016, 2, 16035.	30.5	473
7	A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. Cancer Cell, 2017, 31, 820-832.e3.	16.8	433
8	Lymphangioleiomyomatosis â€” a wolf in sheepâ€™s clothing. Journal of Clinical Investigation, 2012, 122, 3807-3816.	8.2	258
9	Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet, The, 2003, 361, 1348-1349.	13.7	196
10	Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. Journal of Experimental Medicine, 2014, 211, 2249-2263.	8.5	170
11	Lymphangioleiomyomatosis. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 1210-1212.	5.6	168
12	Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	156
13	Aggressive variants of chromophobe renal cell carcinoma. Cancer, 1996, 78, 1756-1761.	4.1	100
14	Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development. PLoS Genetics, 2016, 12, e1006242.	3.5	93
15	Tumour predisposition and cancer syndromes as models to study geneâ€™environment interactions. Nature Reviews Cancer, 2020, 20, 533-549.	28.4	93
16	Renal disease in tuberous sclerosis complex: pathogenesis and therapy. Nature Reviews Nephrology, 2018, 14, 704-716.	9.6	83
17	New developments in the genetics and pathogenesis of tumours in tuberous sclerosis complex. Journal of Pathology, 2017, 241, 219-225.	4.5	67
18	Folliculin regulates cell-cell adhesion, AMPK, and mTORC1 in a cell-type-specific manner in lung-derived cells. Physiological Reports, 2014, 2, e12107.	1.7	53

#	ARTICLE	IF	CITATIONS
19	TSC2 regulates lysosome biogenesis via a non-canonical RAGC and TFEB-dependent mechanism. <i>Nature Communications</i> , 2021, 12, 4245.	12.8	52
20	p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis. <i>Cancer Research</i> , 2017, 77, 3255-3267.	0.9	49
21	TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy. <i>JCI Insight</i> , 2018, 3, .	5.0	49
22	Mechanisms of pulmonary cyst pathogenesis in Birt-Hogg-Dube syndrome: The stretch hypothesis. <i>Seminars in Cell and Developmental Biology</i> , 2016, 52, 47-52.	5.0	48
23	Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis. <i>Chest</i> , 2017, 151, 1302-1310.	0.8	46
24	The Genetics of Pneumothorax. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1344-1357.	5.6	45
25	Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference. <i>Pediatric Neurology</i> , 2016, 60, 1-12.	2.1	43
26	Renal Cell Carcinoma in Tuberous Sclerosis Complex. <i>Genes</i> , 2021, 12, 1585.	2.4	33
27	Metabolic reprogramming in polycystic kidney disease. <i>Nature Medicine</i> , 2013, 19, 407-409.	30.7	32
28	Tuberous Sclerosis Complex 2 Loss Increases Lysophosphatidylcholine Synthesis in Lymphangioleiomyomatosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2015, 53, 33-41.	2.9	30
29	Human Pluripotent Stem Cell-Derived TSC2-Haploinsufficient Smooth Muscle Cells Recapitulate Features of Lymphangioleiomyomatosis. <i>Cancer Research</i> , 2017, 77, 5491-5502.	0.9	29
30	Familial pneumothorax: towards precision medicine. <i>Thorax</i> , 2018, 73, 270-276.	5.6	26
31	Evidence Supporting a Lymphatic Endothelium Origin for Angiomyolipoma, a TSC2-Related Tumor Related to Lymphangioleiomyomatosis. <i>American Journal of Pathology</i> , 2016, 186, 1825-1836.	3.8	24
32	Emerging biomarkers of lymphangioleiomyomatosis. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 95-102.	2.5	22
33	The TSC Complex-mTORC1 Axis: From Lysosomes to Stress Granules and Back. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 751892.	3.7	22
34	Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion. <i>Journal of Experimental Medicine</i> , 2019, 216, 2635-2652.	8.5	20
35	Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells. <i>Oncotarget</i> , 2017, 8, 64714-64727.	1.8	18
36	Tuberous sclerosis complex, mTOR, and the kidney: report of an NIDDK-sponsored workshop. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 306, F279-F283.	2.7	17

#	ARTICLE	IF	CITATIONS
37	Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation. Cancer Research, 2017, 77, 1492-1502.	0.9	17
38	Immunotherapy for Lymphangioleiomyomatosis and Tuberous Sclerosis. Chest, 2019, 156, 1062-1067.	0.8	15
39	A genome-wide association study implicates <i>NR2F2</i> in lymphangioleiomyomatosis pathogenesis. European Respiratory Journal, 2019, 53, 1900329.	6.7	14
40	MITF is a driver oncogene and potential therapeutic target in kidney angiomyolipoma tumors through transcriptional regulation of CYR61. Oncogene, 2021, 40, 112-126.	5.9	14
41	Kidney intercalated cells and the transcription factor FOXi1 drive cystogenesis in tuberous sclerosis complex. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	14
42	Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis. Chest, 2018, 154, 1070-1082.	0.8	13
43	Interleukin-6 mediates PSAT1 expression and serine metabolism in TSC2-deficient cells. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	13
44	Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	13
45	Mesenchymal folliculin is required for alveolar development: implications for cystic lung disease in Birt-Hogg-Dubé syndrome. Thorax, 2020, 75, 486-493.	5.6	12
46	Lysosomal regulation of cholesterol homeostasis in tuberous sclerosis complex is mediated via NPC1 and LDL-R. Oncotarget, 2017, 8, 38099-38112.	1.8	12
47	Rapamycin-upregulated miR-29b promotes mTORC1-hyperactive cell growth in TSC2-deficient cells by downregulating tumor suppressor retinoic acid receptor β^2 (RAR β^2). Oncogene, 2019, 38, 7367-7383.	5.9	11
48	Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for <i>VHL</i> or <i>TSC</i> mutation. Oncotarget, 2017, 8, 17628-17642.	1.8	11
49	Therapeutic Targeting of DGKA-Mediated Macropinocytosis Leads to Phospholipid Reprogramming in Tuberous Sclerosis Complex. Cancer Research, 2021, 81, 2086-2100.	0.9	8
50	Celecoxib in lymphangioleiomyomatosis: results of a phase I clinical trial. European Respiratory Journal, 2020, 55, 1902370.	6.7	7
51	Targeted deletion of Tsc1 causes fatal cardiomyocyte hyperplasia independently of afterload. Cardiovascular Pathology, 2015, 24, 80-93.	1.6	6
52	mTORC1 is a mechanosensor that regulates surfactant function and lung compliance during ventilator-induced lung injury. JCI Insight, 2021, 6, .	5.0	6
53	Serum endostatin levels are associated with diffusion capacity and with tuberous sclerosis-associated lymphangioleiomyomatosis. Orphanet Journal of Rare Diseases, 2019, 14, 72.	2.7	5
54	Generalised mosaicism for TSC2 mutation in isolated lymphangioleiomyomatosis. European Respiratory Journal, 2019, 54, 1900938.	6.7	5

#	ARTICLE	IF	CITATIONS
55	Chromophobe renal cell carcinoma: New genetic and metabolic insights. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 678-681.	1.6	4
56	Seventh BHD international symposium: recent scientific and clinical advancement. Oncotarget, 2022, 13, 173-181.	1.8	4
57	Modeling tuberous sclerosis with organoids. Science, 2022, 375, 382-383.	12.6	4
58	The Codon 72 <i>TP53</i> Polymorphism Contributes to TSC Tumorigenesis through the Notch-Nodal Axis. Molecular Cancer Research, 2019, 17, 1639-1651.	3.4	2
59	Getting to the finish line with mTORC1-targeted therapy. Journal of Clinical Investigation, 2012, 122, 1970-1972.	8.2	2
60	ETV2 regulates PARP-1 binding protein to induce ER stress-mediated death in tuberin-deficient cells. Life Science Alliance, 2022, 5, e202201369.	2.8	2
61	Vitamin D binding protein: a new biomarker of disease severity in lymphangioleiomyomatosis. European Respiratory Journal, 2018, 52, 1801886.	6.7	0